Therefore, we determined the influence of UGT1A1 polymorphism on the prognosis, specifically progression-free survival (PFS), of local cervical cancer patients treated with CPT-11/NDP, including in patients at a high risk for recurrence. This evidence concerns the gene UGT1A1 and cervical cancer.